Global Molecular Diagnostics for Infectious Disease Markets 2018-2019 & 2023

Dublin, March 26, 2018 (GLOBE NEWSWIRE) — The “Global Molecular Diagnostics for Infectious Disease 2019 to 2023 – Markets, Strategies and Trends, Volume & Price Forecasts by Pathogen and by Country” report has been added to’s offering.

Improvements in speed and accuracy drive demand for molecular diagnostic tests for infectious disease. Genetics advances create need for new diagnostics creating a fast moving market driven by technical change.

The Molecular Diagnostics – Infectious Disease sector of the clinical diagnostics industry is poised for record growth. A market that just keeps on growing. In spite of the steady decline of disease prevalence, the diagnostic sector keeps growing. Find out why in the informative report.

Infectious disease testing directly benefits from the explosion in biotechnology, especially genomics. A range of dynamic trends are pushing market growth and company valuations.

Trends like:

  • changing demographics
  • emerging economies and global prosperity
  • biotechnology advances in genetics
  • pathogen evolution
  • climate change
  • globalization
  • the rise of rapid testing

Exciting technical developments especially in the seesaw between sequencing and immunoassay, hold the promise of a dynamic, growing and evolving world market that holds the promise of diagnostics taking the lead in infectious disease eradication.

The report has hundreds of pages of information including a complete list of Current 2016 United States Medicare Fee Payment Schedules to help sharpen your pricing. Again, assistance in using the information is normally provided without additional charges.

Key Topics Covered:

1. Introduction and Market Definition
1.1 What is Molecular Diagnostics
1.2 The Diagnostics Revolution
1.3 Market Definition
1.3.1 Volumes
1.3.2 Prices
1.3.3 Revenue Market Size
1.4 Methodology
1.5 U.S. Medical Market and Clinical Laboratory Testing – Perspective

2. The Infectious Diseases – Market Analysis by Disease
2.1 HIV – Human Immunodeficiency Virus (AIDS)
2.1.1 Virology Classification Structure and genome Tropism Replication cycle Genetic variability
2.1.2 Diagnosis
2.1.3 Testing Antibody tests Point of Care Tests (POCT) Antigen Tests Nucleic acid-based tests (NAT) Other tests used in HIV treatment
2.1.4 Market Opportunity Analysis
2.2 HBV – Hepatitis B
2.2.1 Virology Genome Pathogenesis Hepatitis B virus replication Serotypes and genotypes
2.2.2 Mechanisms
2.2.3 Diagnosis
2.2.4 Market Opportunity Analysis
2.3 HCV – Hepatitis C
2.3.1 Taxonomy
2.3.2 Structure Genome
2.3.3 Molecular biology
2.3.4 Replication
2.3.5 Genotypes Clinical importance
2.3.6 Market Opportunity Analysis
2.4 HPV – Human papillomavirus
2.4.1 Virology E6/E7 proteins Role in cancer E2 research Latency period Clearance
2.4.2 Diagnosis Cervical testing Oral testing Testing men Other testing
2.4.3 Market Opportunity Analysis
2.5 Influenza
2.5.1 Virology Types of virus Influenzavirus A Influenzavirus B Influenzavirus C Structure, properties, and subtype nomenclature Replication
2.5.2 Testing Advantages/Disadvantages of Molecular Assays
2.5.3 Market Opportunity Analysis
2.6 CTGC – Chlamydia/Gonorhea
2.6.1 Gonorrhea Diagnosis Screening
2.6.2 Chlamydia Diagnosis Screening
2.6.3 Testing Nucleic acid amplification tests (NAATs). Performance of NAAT Tests
2.6.4 Market Opportunity Analysis
2.7 Tuberculosis
2.7.1 Mycobacteria
2.7.2 Diagnosis Active tuberculosis Latent tuberculosis
2.7.3 Epidemiology
2.7.4 Molecular Diagnostic Tests
2.7.5 Market Opportunity Analysis
2.8 MRSA – Methicillin-resistant Staphylococcus aureus
2.8.1 Diagnosis
2.8.2 FDA Approved Molecular Tests
2.8.3 Market Opportunity Analysis
2.9 VRE – Vancomycin-resistant Enterococcus
2.9.1 FDA Approved MDx Tests for VRE
2.9.2 Market Opportunity Analysis
2.10 Blood Screening
2.10.1 Collection and Testing
2.10.2 FDA Approved Multiplex Assays
2.10.3 Market Opportunity Analysis

3. Industry Overview
3.1 Industry Participants
3.1.1 Supplier/pharmaceutical
3.1.2 Independent lab specialized/esoteric
3.1.3 Independent lab national/regional
3.1.4 Independent lab analytical
3.1.5 Public National/regional lab
3.1.6 Hospital lab
3.1.7 Physician lab
3.1.8 Audit body
3.2 The Clinical Laboratory Market Segments
3.2.1 Traditional Market Segmentation
3.2.2 Laboratory Focus and Segmentation
3.3 Industry Structure
3.3.1 Hospital Testing Share
3.3.2 Economies of Scale Hospital vs. Central Lab
3.3.3 Physician Office Lab’s
3.3.4 Physician’s and POCT
3.4 Profiles of Key MDx Companies
3.4.1 Abbott Diagnostics
3.4.2 Alere (Abbott)
3.4.3 BD Diagnostics
3.4.4 Beckman Coulter
3.4.5 bioMrieux
3.4.6 Bio-Rad Laboratories
3.4.7 Cepheid
3.4.8 DiaSorin
3.4.9 Eiken Chemical
3.4.10 Grifols
3.4.11 Hologic
3.4.12 Illumina
3.4.13 Janssen Diagnostics
3.4.14 Luminex
3.4.15 Meridian Bioscience
3.4.16 Qiagen
3.4.17 Quidel
3.4.18 Roche Molecular Diagnostics
3.4.19 Siemens Healthineers
3.4.20 Thermo Fisher

4. Market Trends
4.1 Factors Driving Growth
4.1.1 New Genotypes Creating New Markets
4.1.2 Aging Population a Boon for All Diagnostics
4.1.3 Developing World Driving ID Dx Growth.
4.1.4 Point of Care – Why Centralization is Losing Steam
4.1.5 Self Testing
4.1.6 The Need for Speed
4.2 Factors Limiting Growth
4.2.1 Lower Costs
4.2.2 Infectious Disease is Declining.
4.2.3 Wellness Hurts.
4.2.4 Economic Growth improves Living Standards
4.3 Instrumentation and Automation
4.3.1 Instruments Key to Market Share
4.3.2 The Shrinking Machine.
4.3.2 Multiplex, Point of Care and The Speed Factor.
4.4 Diagnostic Technology Development
4.4.1 The Sepsis Testing Market – A New Direction?
4.4.2 POCT/Self Testing as a Disruptive Force
4.4.3 The Genetics Play – One Test for All Known Infections
4.4.4 Antibiotic Resistance Genes – Simplifying Diagnostics

5. Molecular Dx – Infectious Disease Recent Developments
5.1 Recent Developments – Importance and How to Use This Section
5.1.1 Importance of These Developments
5.1.2 How to Use This Section
5.3 QIAGEN enters into agreement to acquire STAT-Dx
5.4 Curetis subsidiary Ares Genetics wins incubator stay in Silicon Valley
5.5 Quidel Receives FDA Clearance for Its Point-of-Care Sofia Lyme Fluorescent Immunoassay
5.6 ‘Origami’ diagnostics breakthrough set to benefit developing-world farmers
5.7 NYU researchers adapt HIV test to Zika virus
5.8 GA-EMS receives diagnostic device contract
5.9 Biocartis & Immunexpress Sign Partnership for Sepsis
5.10 PerkinElmer to Acquire Euroimmun for $1.3B
5.11 Alveo Closes Financing to Create Accessible Diagnostics Devices
5.12 Siemens Healthineers completes takeover of Fast Track Diagnostics
5.13 Sekisui Diagnostics Enters Strategic Alliance with Mesa Biotech Inc
5.14 Chembio and FIND to Develop Point-of-Care Multiplex Test
5.15 Locus Biosciences and IDbyDNA Partner to Develop Companion Diagnostic Test
5.16 Alere bags FDA nod for rapid flu diagnostic
5.17 FDA approves tests of tick-borne disease to protect blood supply
5.18 Qiagen Trichomonas Assay Gets CE Mark
5.19 Vela Diagnostics HSV Test Gets FDA Clearance

Companies Mentioned

  • Abbott Diagnostics
  • Alere
  • Alveo
  • BD Diagnostics
  • Beckman Coulter
  • Bio-Rad Laboratories
  • Biocartis
  • Cepheid
  • Chembio
  • Curetis
  • DiaSorin
  • Eiken Chemical
  • Euroimmun
  • FIND
  • GA-EMS
  • Grifols
  • Hologic
  • IDbyDNA
  • Illumina
  • Immunexpress
  • Janssen Diagnostics
  • Locus Biosciences
  • Luminex
  • Meridian Bioscience
  • Mesa Biotech Inc
  • Molecular Dx
  • ‘Origami’ diagnostics
  • PerkinElmer
  • Qiagen
  • Quidel
  • Roche Molecular Diagnostics
  • STAT-Dx
  • Sekisui Diagnostics
  • Siemens
  • Thermo Fisher
  • Vela Diagnostics
  • bioMrieux

For more information about this report visit


         Laura Wood, Senior Manager
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
         Related Topics: Infectious Disease Testing, Molecular Diagnostics